Xtx Topco LTD Poseida Therapeutics, Inc. Transaction History

Xtx Topco LTD

$1.13 Billion
Q4 2024

A detailed history of Xtx Topco LTD transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 71,040 shares of PSTX stock, worth $674,880. This represents 0.06% of its overall portfolio holdings.

Number of Shares

71,040

Previous 182,888 61.16%

Holding current value

$674,880

Previous $523,000 30.21%

% of portfolio

0.06%

Previous 0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$2.37 - $9.6 $265,079 - $1.07 Million	-111,848 Reduced 61.16%	71,040 $681,000
Q3 2024 Nov 14, 2024	BUY	$2.7 - $4.04 $158,184 - $236,691	58,587 Added 47.13%	182,888 $523,000
Q2 2024 Aug 12, 2024	BUY	$2.0 - $3.46 $67,302 - $116,432	33,651 Added 37.12%	124,301 $362,000
Q1 2024 May 13, 2024	BUY	$2.76 - $4.13 $209,715 - $313,813	75,984 Added 518.1%	90,650 $289,000
Q4 2023 Feb 13, 2024	SELL	$1.83 - $3.51 $47,792 - $91,667	-26,116 Reduced 64.04%	14,666 $49,000
Q3 2023 Nov 13, 2023	SELL	$1.62 - $2.79 $312,191 - $537,663	-192,711 Reduced 82.53%	40,782 $97,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.4 $136,790 - $280,173	82,404 Added 54.54%	233,493 $410,000
Q1 2023 May 12, 2023	BUY	$3.08 - $8.73 $83,323 - $236,172	27,053 Added 21.81%	151,089 $465,000
Q4 2022 Feb 14, 2023	BUY	$3.33 - $6.38 $359,160 - $688,121	107,856 Added 666.6%	124,036 $657,000
Q3 2022 Nov 14, 2022	BUY	$2.43 - $4.51 $39,317 - $72,971	16,180 New	16,180 $57,000

Others Institutions Holding PSTX

# of Institutions

119

Shares Held

40.7M

Call Options Held

135K

Put Options Held

439K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $815M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account